Hims & Hers Health, Inc.
27.71USD
-1.4200 (-4.87%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on HIMS.
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 526.9M | 872.0M | 1.5B | 2.3B | 3.2B | 4.0B |
| Q1 | 101.3M | 190.8M | 278.2M | 586.0M | 608.1M | — |
| Q2 | 113.6M | 207.9M | 315.6M | 544.8M | 753.2M | — |
| Q3 | 144.8M | 226.7M | 401.6M | 599.0M | 892.8M | — |
| Q4 | 167.2M* | 246.6M* | 481.1M* | 617.8M* | 954.6M | — |
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | -.320 | -.110 | .530 | .510 | -.560 | .419 |
| Q1 | -.080 | -.050 | .050 | .200 | -.400 | — |
| Q2 | -.100 | -.030 | .060 | .170 | -.370 | — |
| Q3 | -.090 | -.040 | .320 | .060 | .056 | — |
| Q4 | -.053* |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
Revenue to net income
| .006* |
| .110* |
| .080* |
| .115 |
| — |
Debt level and coverage